IL165115A0 - Novel crystalline forms of gatifloxacin - Google Patents

Novel crystalline forms of gatifloxacin

Info

Publication number
IL165115A0
IL165115A0 IL16511504A IL16511504A IL165115A0 IL 165115 A0 IL165115 A0 IL 165115A0 IL 16511504 A IL16511504 A IL 16511504A IL 16511504 A IL16511504 A IL 16511504A IL 165115 A0 IL165115 A0 IL 165115A0
Authority
IL
Israel
Prior art keywords
gatifloxacin
crystalline forms
novel crystalline
novel
forms
Prior art date
Application number
IL16511504A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/735,029 external-priority patent/US7301024B2/en
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL165115A0 publication Critical patent/IL165115A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL16511504A 2002-05-10 2004-11-09 Novel crystalline forms of gatifloxacin IL165115A0 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US37951002P 2002-05-10 2002-05-10
US38909302P 2002-06-14 2002-06-14
US40167202P 2002-08-06 2002-08-06
US40274902P 2002-08-12 2002-08-12
US40986002P 2002-09-10 2002-09-10
US42333802P 2002-11-01 2002-11-01
US43296102P 2002-12-12 2002-12-12
US44481203P 2003-02-03 2003-02-03
US44806203P 2003-02-15 2003-02-15
PCT/US2003/014811 WO2003094919A2 (fr) 2002-05-10 2003-05-12 Nouvelles formes cristallines de gatifloxacine
US10/735,029 US7301024B2 (en) 2002-12-12 2003-12-12 Crystalline forms of gatifloxacin and processes for preparation

Publications (1)

Publication Number Publication Date
IL165115A0 true IL165115A0 (en) 2005-12-18

Family

ID=37772994

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16511504A IL165115A0 (en) 2002-05-10 2004-11-09 Novel crystalline forms of gatifloxacin

Country Status (10)

Country Link
US (6) US20060258674A1 (fr)
EP (1) EP1503762A2 (fr)
JP (1) JP2005534633A (fr)
KR (1) KR20040106518A (fr)
CN (1) CN1665504A (fr)
AU (1) AU2003232113A1 (fr)
CA (1) CA2485262A1 (fr)
IL (1) IL165115A0 (fr)
PL (1) PL373788A1 (fr)
WO (1) WO2003094919A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511618A (ja) * 2002-12-12 2006-04-06 テバ ファーマシューティカル インダストリーズ リミティド ガチフロキサシンの結晶形態および調製の方法
AU2003304118A1 (en) * 2003-05-19 2004-12-03 Hetero Drugs Limited Purification methods of gatifloxacin and a novel form of gatifloxacin
ES2232310B1 (es) * 2003-11-13 2006-08-01 Quimica Sintetica, S.A. Formula cristalina no higroscopica de gatifloxacino.
US20050171044A1 (en) * 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
WO2005118546A1 (fr) * 2004-06-04 2005-12-15 Matrix Laboratories Ltd Nouvelles formes cristallines de gatifloxacine
TW200800954A (en) * 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
BRPI0809579B8 (pt) 2007-03-29 2021-05-25 Progenics Pharm Inc formas cristalinas e seus usos
US7943782B2 (en) * 2007-10-19 2011-05-17 Abbott Laboratories Crystalline chemotherapeutic
TWI526437B (zh) * 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
BR112016011065B1 (pt) 2013-11-15 2022-10-25 Akebia Therapeutics, Inc Composto cristalino e seu uso, composição farmacêutica e seu uso, forma de dosagem, método para preparar um composto
CN111337666B (zh) * 2020-02-12 2021-04-02 山东大学 I-motif重组介导的FRET探针及其原位成像癌细胞表面蛋白质同源二聚化的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH089597B2 (ja) * 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
WO1993015070A1 (fr) * 1992-01-31 1993-08-05 Chugai Seiyaku Kabushiki Kaisha Cristal d'hydrate de derive d'acide quinolonecarboxylique
JP3449658B2 (ja) * 1994-12-21 2003-09-22 杏林製薬株式会社 安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法
US6413969B1 (en) * 2000-09-13 2002-07-02 Bristol-Myers Squibb Company Gatifloxacin pentahydrate
CA2495271A1 (fr) * 2002-08-14 2004-08-19 Teva Pharmaceutical Industries Ltd Synthese de gatifloxacine
JP2006511618A (ja) * 2002-12-12 2006-04-06 テバ ファーマシューティカル インダストリーズ リミティド ガチフロキサシンの結晶形態および調製の方法

Also Published As

Publication number Publication date
JP2005534633A (ja) 2005-11-17
US20060252772A1 (en) 2006-11-09
KR20040106518A (ko) 2004-12-17
PL373788A1 (en) 2005-09-19
CN1665504A (zh) 2005-09-07
EP1503762A2 (fr) 2005-02-09
US20060252770A1 (en) 2006-11-09
US20060258676A1 (en) 2006-11-16
CA2485262A1 (fr) 2003-11-20
WO2003094919A2 (fr) 2003-11-20
US20060252771A1 (en) 2006-11-09
AU2003232113A1 (en) 2003-11-11
US20060258675A1 (en) 2006-11-16
US20060258674A1 (en) 2006-11-16
WO2003094919A3 (fr) 2004-03-18

Similar Documents

Publication Publication Date Title
AU2003230192A1 (en) Novel crystalline forms of aripiprazole
IL165584A0 (en) Novel formate salt of o-desmethyl-venlafaxine
HK1103294A1 (en) Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride (6r)-l--
ZA200507344B (en) Novel crystalline modification of the anhydrate of boscalid
IL172006A0 (en) Novel crystalline forms of valacyclovir hydrochloride
IL166592A0 (en) Novel crystalline forms of gatifloxacin
IL165115A0 (en) Novel crystalline forms of gatifloxacin
AU2003245029A1 (en) Novel crystalline forms of donepezil hydrochloride
AU2003297594A8 (en) Crystalline form
AU2003245027A1 (en) Novel crystalline forms of ziprasidone hydrochloride
AU2003232719A1 (en) Novel crystalline forms of valacyclovir hydrochloride
AU2003295638A8 (en) Novel inhibitors of beta-lactamase
IL165690A0 (en) Novel crystalline forms of gatifloxacin
IL174969A0 (en) Crystalline forms of (+)-and (-) erythro-mefloquine hydrochloride
AU2003217438A1 (en) Novel crystalline forms of levetiracetam
AU2003298725A8 (en) Preparation of metallotexaphyrins
PL375437A1 (en) Synthesis of gatifloxacin
AU2003300874A1 (en) Crystalline forms of gatifloxacin and processes for preparation
AU2003217437A1 (en) Novel crystalline forms of lamotrigine
EP1486485A4 (fr) Nouveaux cristaux de derive de 5-hydroxycarbamimidoyl-2-hydroxybenzenesulfonamide
AU2003230194A1 (en) Novel crystalline forms of gatifloxacin
IL174063A0 (en) Crystalline form of gatifloxacin
AU2003238668A1 (en) Novel crystalline forms of valdecoxib
AU2003209670A1 (en) Novel crystalline forms of trandolapril
GB0228533D0 (en) Crystalline form